成纖維細(xì)胞生長(zhǎng)因子23(FGF23)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法)
ELISA Kit for Fibroblast Growth Factor 23 (FGF23)
ADHR; HYPF; HPDR2; PHPTC; Phosphatonin; Tumor-derived hypophosphatemia-inducing factor
- 編號(hào)UCEA746Ra
- 物種Rattus norvegicus (Rat，大鼠) 相同的名稱(chēng)，不同的物種。
- 實(shí)驗(yàn)方法競(jìng)爭(zhēng)抑制
- 反應(yīng)時(shí)長(zhǎng)2h
- 檢測(cè)范圍62.5-1,000pg/mL
- 靈敏度最小可檢測(cè)劑量小于等于21.6pg/mL.
- 樣本類(lèi)型serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- 下載 英文說(shuō)明書(shū) 中文說(shuō)明書(shū)
- 規(guī)格 48T96T 96T*5 96T*10 96T*100
- 價(jià)格 ¥ 1436 ¥ 2052 ¥ 9234 ¥ 17442 ¥ 143640
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷(xiāo)商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
實(shí)驗(yàn)結(jié)果圖
-
標(biāo)準(zhǔn)曲線(xiàn)圖
-
通過(guò)ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
本試劑盒用于檢測(cè)成纖維細(xì)胞生長(zhǎng)因子23(FGF23)，經(jīng)檢測(cè)與其它相似物質(zhì)無(wú)明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來(lái)源的限制，不可能完成對(duì)所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測(cè)，因此本試劑盒有可能與未經(jīng)檢測(cè)的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的成纖維細(xì)胞生長(zhǎng)因子23(FGF23)（加標(biāo)樣品），重復(fù)測(cè)定并計(jì)算其均值，回收率為測(cè)定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 97-105 | 102 |
| EDTA plasma(n=5) | 80-99 | 91 |
| heparin plasma(n=5) | 97-105 | 101 |
精密度
精密度用樣品測(cè)定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對(duì)低、中、高值定值樣本進(jìn)行定量檢測(cè),每份樣本連續(xù)測(cè)定20 次，分別計(jì)算不同濃度樣本的平均值及SD值。
批間差：選取3個(gè)不同批次的試劑盒分別對(duì)低、中、高值定值樣本進(jìn)行定量測(cè)定，每個(gè)樣本使用同一試劑盒重復(fù)測(cè)定8次，分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線(xiàn)性
在定值血清及血漿樣本內(nèi)加入適量的成纖維細(xì)胞生長(zhǎng)因子23(FGF23)，并倍比稀釋成1:2，1:4，1:8，1:16的待測(cè)樣本，線(xiàn)性范圍即為稀釋后樣本中成纖維細(xì)胞生長(zhǎng)因子23(FGF23)含量的測(cè)定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 95-103% | 87-96% | 93-105% | 80-92% |
| EDTA plasma(n=5) | 98-105% | 93-101% | 80-89% | 80-104% |
| heparin plasma(n=5) | 88-96% | 80-105% | 96-105% | 85-104% |
穩(wěn)定性
經(jīng)測(cè)定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對(duì)試劑盒破壞前后檢測(cè)值的影響，實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致，尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來(lái)進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本的準(zhǔn)備；
2. 加樣（標(biāo)準(zhǔn)品及樣本）50µL，
加入50µL檢測(cè)液A(臨用前配制);
37°C溫育1小時(shí)。
3. 洗板3次；
4. 加檢測(cè)溶液B100µL，37°C孵育30分鐘；
5. 洗板5次；
6. 加TMB底物90µL，37°C孵育10-20分鐘；
7. 加終止液50µL，立即450nm讀數(shù)。
實(shí)驗(yàn)原理
本試劑盒應(yīng)用競(jìng)爭(zhēng)抑制酶聯(lián)免疫分析法測(cè)定標(biāo)本中待測(cè)物質(zhì)水平。將成纖維細(xì)胞生長(zhǎng)因子23(FGF23)單克隆抗體包被微孔板，制成固相載體，往包被抗體的微孔中同時(shí)加入生物素標(biāo)記的抗原和待測(cè)抗原(標(biāo)準(zhǔn)品或樣本)，待測(cè)抗原與生物素標(biāo)記抗原對(duì)特異性抗體進(jìn)行競(jìng)爭(zhēng)結(jié)合。溫育后經(jīng)洗滌去掉未結(jié)合物，然后加入HRP標(biāo)記的親和素，經(jīng)過(guò)溫育和徹底洗滌后加入底物TMB顯色。TMB在過(guò)氧化物酶的催化下轉(zhuǎn)化成藍(lán)色，并在酸的作用下轉(zhuǎn)化成最終的黃色。待測(cè)標(biāo)本濃度越高，標(biāo)記抗原和抗體的結(jié)合就越受到抑制，顯色愈淺。顯色的深淺與酶量呈正相關(guān)，而與樣品中待測(cè)物質(zhì)含量呈負(fù)相關(guān)。用酶標(biāo)儀在450nm波長(zhǎng)下測(cè)定吸光度（O.D.值），計(jì)算樣品濃度。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Rattus norvegicus (Rat，大鼠) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| URPA746Ra01 | 成纖維細(xì)胞生長(zhǎng)因子23(FGF23)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UAPA746Ra01 | 成纖維細(xì)胞生長(zhǎng)因子23(FGF23)活性蛋白 | Cell?culture;?Activity?Assays. |
| UPAA746Ra01 | 成纖維細(xì)胞生長(zhǎng)因子23(FGF23)多克隆抗體 | WB; IHC; ICC; IP. |
| UMAA746Ra21 | 成纖維細(xì)胞生長(zhǎng)因子23(FGF23)單克隆抗體 | WB; IHC; ICC; IP. |
| USEA746Ra | 成纖維細(xì)胞生長(zhǎng)因子23(FGF23)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| UCEA746Ra | 成纖維細(xì)胞生長(zhǎng)因子23(FGF23)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| ULMA746Ra | 成纖維細(xì)胞生長(zhǎng)因子23(FGF23)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
| UKSA746Ra11 | 成纖維細(xì)胞生長(zhǎng)因子23(FGF23)檢測(cè)試劑盒DIY材料(酶聯(lián)免疫吸附試驗(yàn)法) | Main materials for "Do It (ELISA Kit) Yourself". |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Journal of international medicine | Prognostic impact of renal function in precapillary pulmonary hypertension [Pubmed: 24011362] |
| BMC Nephrology | FGF-23 associated with the progression of coronary artery calcification in hemodialysis patients [Pubmed: 24180481] |
| Journal of Clinical Densitometry | Lower Fibroblast Growth Factor 23 Levels in Young Adults With Crohn Disease as a Possible Secondary Compensatory Effect on the Disturbance of Bone and Mineral Metabolism [Pubmed: 23623649] |
| J Intern Med. | Prognostic impact of renal function in precapillary pulmonary hypertension. [Pubmed:24011362] |
| Journal of Bone and Mineral Research | Adverse effects of osteocytic constitutive activation of ?-catenin on bone strength and bone growth [Pubmed:25639729] |
| Nefrologia | Fibroblast growth factor is associated to left ventricular mass index, anemia and low values of transferrin saturation El factor de crecimiento fibroblástico está asociado con el índice de masa ventricular izquierda, anemia y niveles bajos de saturación de la transferrina [PubMed: 26394828] |
| Medicine (Baltimore) | An Attempt to Evaluate Selected Aspects of “Bone–Fat Axis” Function in Healthy Individuals and Patients With Pancreatic Cancer [PubMed: 26266370] |
| Ann Biol Clin (Paris) | Les biomarqueurs des calcifications vasculaires: quelles limites analytiques pour leur transfert de la recherche bioclinique à la pratique? [PubMed: 26069069] |
| Scandinavian Journal of Gastroenterology | High-dose fast infusion of parenteral iron isomaltoside is efficacious in inflammatory bowel disease patients with iron-deficiency anaemia without profound changes in phosphate or fibroblast growth factor 23 [Pubmed:27326766] |
| PLOS?ONE | Prostaglandin-E2?Mediated?Increase?in?Calcium?and?Phosphate?Excretion?in a?Mouse?Model?ofDistal?Nephron?Salt?Wasting. [pubmed:27442254] |
| Journal of Laboratory Diagnostics | Evaluation of concentration fibroblast growth factor FGF-23 in hemodialysed patients and after kidney transplantation [publication:312592751] |
| Journal of Integrative Nephrology & Andrology | Associations between serum fibroblast growth factor 23 level and intradialytic hypotension in hemodialysis patients [issn:2394-2916] |
| Journal of Renal Nutrition | ADAM17, a New Player in the Pathogenesis of Chronic Kidney Disease-Mineral and Bone Disorder. [pubmed:29056164] |
| Experimental Biology and Medicine(Maywood) | Effect of cross-linked chitosan iron (III) on vascular calcification in uremic rats [Pubmed:29763365] |
| Psychiatry Research | Cerebrospinal fluid FGF23 levels correlate with a measure of impulsivity [Pubmed:29677623] |
| BMC?Pediatrics | Serum and urine FGF23 and IGFBP-7 for the prediction of acute kidney injury in critically ill children [Pubmed:29907141] |
| Medical Science Monitor | Effect of Salt Intervention on Serum Levels of Fibroblast Growth Factor 23 (FGF23) in Chinese Adults: An Intervention Study [Pubmed:29608553] |
| International Journal of Chronic Obstructive Pulmonary Disease | Disconnection of pulmonary and systemic arterial stiffness in COPD [Pubmed:29881265] |
| Saudi?journal of?kidney?diseases and transplantation | Prevalence of cardiac arrhythmia and risk factors in chronic kidney disease patients [Pubmed:29970732] |
| Nephrology Dialysis?Transplantation | High-serum phosphate and parathyroid hormone distinctly regulate bone loss and vascular calcification in experimental chronic kidney disease [Pubmed: 30189026] |
| BioFactors? | Alteration in serum concentrations of FGF19, FGF21, and FGF23 in patients with urothelial carcinoma [Pubmed: 30334297] |
| Biological?Trace?Element?Research | Altered Mineral Metabolism and Disequilibrium Between Calcification Promoters and Inhibitors in Chronic Hemodialysis Patients [Pubmed: 30847765] |
| Clin Implant Dent Relat Res. | Evaluation of FGF‐23 and 25(OH)D3 levels in peri‐implant sulcus fluid in peri‐implant health and diseases [Pubmed: 31407857] |
| JACC-Cardiovascular Imaging | PREVALANCE AND PROGRESSION OF CARDIOVASCULAR CALCIFICATIONS IN HAEMODIALYSIS PATIENTS [Pubmed: 28797410] |
| Saudi J Kidney Dis Transpl | Serum fibroblast growth factor 23 levels do not correlate with carotid intima-media thickness in patients with chronic kidney disease [Pubmed: 31696838] |
| Biomedicine & Pharmacotherapy | MiRNA-192-5p attenuates airway remodeling and autophagy in asthma by targeting MMP-16 and ATG7 [Pubmed: 31918268] |
| Is Serum FGF-23 Associated with Subclinic Atherosclerosis in Patients with AA Amyloidosis? [] | |
| THE RELATIONSHIP BETWEEN ARTERIAL STIFNESS AND 25-(OH) VITAMIN D, FGF 23 IN MAINTENANCE HEMODIALYSIS PATIENTS [] | |
| THE RELATIONSHIP BETWEEN ARTERIAL STIFFNESS AND 25-(OH) VITAMIN D, FGF 23 IN MAINTENANCE HEMODIALYSIS PATIENTS KRON?K ?- [] | |
| Calcif Tissue Int | The Measurement and Interpretation of Fibroblast Growth Factor 23 (FGF23) Concentrations [Pubmed:35665817] |
| European Journal of Medical Genetics | Genetic and clinical profile of patients with hypophosphatemic rickets [Pubmed:35738466] |
| African Health Sciences | Fibroblast Growth Factor 23 (FGF 23) and intact parathyroid hormone (iPTH) as markers of mineral bone disease among Nigerians with non-diabetic kidney disease [] |
